literature

HIV mutation literature information.

Computing the Amino Acid Specificity of Fluctuations in Biomolecular Systems.

PMID: 26626694 2006 Journal of chemical theory and computation

Abstract: We apply the new method to HIV-1 protease in its wild-type form and to a V82F-I84V mutant that shows resistance to protease inhibitors.

Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.

PMID: 15572008 2005 Journal of clinical virology

Abstract: For the protease gene, all three assays detected the I84V (n = 1), M46I (n = 1), and L90M (n = 1) mutations.

Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

PMID: 15748098 2005 Drugs

Abstract: When used with ritonavir, the accumulation of six or more mutations among L10F/I/V, K20M/R, E35D, R41K, I54V, L63P, V82A/F/T/S and I84V leads to clear decrease in viral response to treatment.

[Genotypic resistence in patients infected with HIV and its correlation with therapy].

PMID: 15871775 2005 Medicina clinica

Abstract: Moreover, P mutations were detected in 59.38% of cases, being V82A, L90M and I84V the most frequent ones.

Tipranavir: a ritonavir-boosted protease inhibitor.

PMID: 16060700 2005 Drugs

Abstract: Analysis of clinical isolates from treatment-experienced patients identified the following tipranavir resistance-associated HIV protease mutations: L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D, I84V.

Treatment response and drug resistance in patients infected with HIV type 1 group O viruses.

PMID: 16060830 2005 AIDS research and human retroviruses

Abstract: Another selected mutations K70N, V75A, and M184V at the RT, and D30D/N and I84V at the protease while failing on indinavir.

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.

PMID: 16122817 2005 Antiviral research

Abstract: At the end of the selection experiments, viruses harbouring 10 mutations in the protease (L10F, I13V, V32I, L33F, M36I, K45I, I54V, A71V, V82L, I84V) as well as a mutation in the CA/SP1 gag cleavage site were selected and showed 87-fold decreased susceptibility to tipranavir.

Abstract: Characterization of the selected variants revealed that the first mutations to be selected were L33F and I84V in the viral

Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

PMID: 16218957 2005 The FEBS journal

Abstract: PR(I84V) showed reduced van der Waals interactions with inhibitor compared with

Abstract: HIV-1 protease (PR) and two drug-resistant variants--PR with the V82A mutation (PR(V82A)) and PR with the I84V mutation (PR(I84V))--were studied using reduced peptide analogs of five natural cleavage sites (CA-p2, p2-NC, p6pol-PR, p1-p6 and NC-p1) to understand the structural and kinetic changes.

Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.

PMID: 19825125 2005 Journal of the International AIDS Society

Table: I84V

Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure.

PMID: 14759236 2004 Clinical microbiology and infection

Abstract: Using HIV-1 variants resistant to the protease inhibitors saquinavir (G48V/L90M) or indinavir (A71V/V82T/I84V), viral replication was studied in the presence or absence of inhibitor and a mutation at position 63.

Browser Board

Co-occurred Entities

Filtrator